Literature DB >> 16732205

Transpupillary thermotherapy for subfoveal leaks in central serous chorioretinopathy.

D Shukla1, C Kolluru, T P Vignesh, S Karthikprakash, R Kim.   

Abstract

AIM: To evaluate transpupillary thermotherapy (TTT) for the treatment of subfoveal focal leaks in central serous chorioretinopathy (CSC).
METHODS: The patients presenting with long-standing CSC, but without the features of chronicity, were offered the options of TTT, photodynamic therapy (for subfoveal leaks), photocoagulation (for extrafoveal leaks), or observation. The patients who opted for TTT or observation were enrolled in this study. TTT was performed using a spot diameter of 0.5 mm for 1 min. Best-corrected visual acuity (BCVA), status of macular detachment, and fluorescein angiographic status were evaluated at 1, 3, and 6 months.
RESULTS: This study included 39 patients (40 eyes) with CSC between 4 and 12 months, of whom 25 patients (25 eyes) opted for TTT for subfoveal leaks. Fourteen patients (15 eyes) were followed up without treatment. The groups were comparable in age, sex, and baseline BCVA. Minimum follow-up was 6 months. Within 3 months, TTT resulted in the resolution of the serous detachment in 24 (96%) eyes with a single session; one eye required a repeat treatment. Eight control eyes demonstrated persisting CSC at the last follow-up. Visual acuity improved in 23 (92%) treated and five (33%) control eyes; the difference in outcome was statistically significant (P<0.001). One case developed choroidal neovascularization, which resolved with visual recovery to 20/20 after repeat-TTT.
CONCLUSION: TTT resulted in the resolution of CSC with subfoveal angiographic leaks with significant improvement in visual outcome, in comparison to the natural history of persistent CSC.

Entities:  

Mesh:

Year:  2006        PMID: 16732205     DOI: 10.1038/sj.eye.6702449

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN: 0950-222X            Impact factor:   3.775


  14 in total

1.  Central serous chorioretinopathy after blunt trauma.

Authors:  Claudia Maria Prospero Ponce; Hasan M Mohidat; Charles A Garcia
Journal:  BMJ Case Rep       Date:  2012-05-26

Review 2.  Lack of positive effect of intravitreal bevacizumab in central serous chorioretinopathy: meta-analysis and review.

Authors:  Y-R Chung; E J Seo; H M Lew; K H Lee
Journal:  Eye (Lond)       Date:  2013-11-08       Impact factor: 3.775

3.  Comparison of half-dose photodynamic therapy and 689 nm laser treatment in eyes with chronic central serous chorioretinopathy.

Authors:  Andrea Russo; Raffaele Turano; Francesco Morescalchi; Elena Gambicorti; Anna Cancarini; Sarah Duse; Ciro Costagliola; Francesco Semeraro
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2017-03-10       Impact factor: 3.117

Review 4.  Central serous chorioretinopathy: update on pathophysiology and treatment.

Authors:  Benjamin Nicholson; Jason Noble; Farzin Forooghian; Catherine Meyerle
Journal:  Surv Ophthalmol       Date:  2013 Mar-Apr       Impact factor: 6.048

5.  Long-Term Outcome of Half-Dose Verteporfin Photodynamic Therapy for the Treatment of Central Serous Chorioretinopathy (An American Ophthalmological Society Thesis).

Authors:  Timothy Y Y Lai; Raymond L M Wong; Wai-Man Chan
Journal:  Trans Am Ophthalmol Soc       Date:  2015

6.  Role of Transpupillary Thermotherapy in Central Serous Chorio-Retinopathy.

Authors:  V Mathur; Jks Parihar; R Maggon; S K Mishra
Journal:  Med J Armed Forces India       Date:  2011-07-21

7.  Intravitreal bevacizumab versus low-fluence photodynamic therapy for treatment of chronic central serous chorioretinopathy.

Authors:  Francesco Semeraro; Mario R Romano; Paola Danzi; Francesco Morescalchi; Ciro Costagliola
Journal:  Jpn J Ophthalmol       Date:  2012-08-23       Impact factor: 2.447

8.  Large-spot subthreshold transpupillary thermotherapy for chronic serous macular detachment.

Authors:  Giuseppe Lo Giudice; Valentina de Belvis; Marco Tavolato; Alessandro Galan
Journal:  Clin Ophthalmol       Date:  2011-03-14

9.  Transpupillary thermotherapy for atypical central serous chorioretinopathy.

Authors:  Ryosuke Kawamura; Hidenao Ideta; Hideyuki Hori; Kenya Yuki; Tsuyoshi Uno; Tatsurou Tanabe; Kazuo Tsubota; Tsutomu Kawasaki
Journal:  Clin Ophthalmol       Date:  2012-01-25

Review 10.  Advances in the treatment of central serous chorioretinopathy.

Authors:  Marwan A Abouammoh
Journal:  Saudi J Ophthalmol       Date:  2015-01-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.